Search

everythinglearnresearchcommunity

for

Search:↓

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Dutasteride and finasteride affect different cell types differently.

NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.

Finasteride may improve prostate cancer treatment outcomes.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Minoxidil can reduce functions related to androgen receptors.

New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.

Analog 23 is a promising compound for prostate cancer treatment.

Mutations in certain receptors can cause diseases and offer new treatment options.

ERG increases SOX9, promoting prostate cancer growth and invasion.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

New compounds may help treat prostate cancer by reducing cell growth.

New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.

Different drugs can treat high male hormone levels in women, but they have various effects and some may harm a fetus.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

The androgen receptor's shape-changing ability helps it function but can lead to cancer treatment resistance.

Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.

Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.

Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

A new compound, 3a, effectively fights prostate cancer better than finasteride.

A new genetic change causing early stop in the androgen receptor gene was found in a patient with androgen insensitivity syndrome.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

The balance between androgen receptor and p53 is crucial for sebaceous gland differentiation.

Androgen receptors are key for development and health, affecting conditions like prostate cancer and male pattern baldness.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Male genital development is driven by androgen signaling and understanding it could help address congenital anomalies.

Insufficient androgen action in male fetuses can cause genital development issues due to genetic mutations or environmental chemicals.